View ValuationKuangli Bio-Tech Holdings 将来の成長Future 基準チェック /06現在、 Kuangli Bio-Tech Holdingsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Electronic 収益成長33.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 20First quarter 2026 earnings released: NT$0.40 loss per share (vs NT$0.46 loss in 1Q 2025)First quarter 2026 results: NT$0.40 loss per share. Revenue: NT$85.8m (down 22% from 1Q 2025). Net loss: NT$38.7m (loss widened 6.0% from 1Q 2025).Reported Earnings • Mar 20Full year 2025 earnings released: NT$2.07 loss per share (vs NT$2.52 loss in FY 2024)Full year 2025 results: NT$2.07 loss per share. Revenue: NT$377.0m (down 1.1% from FY 2024). Net loss: NT$193.0m (loss widened 12% from FY 2024).お知らせ • Mar 16Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026. Location: 15 floor no,99, fu hsing n. rd., songshan district, taipei city TaiwanNew Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$170m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$3.04b market cap, or US$97.2m).Reported Earnings • Nov 18Third quarter 2025 earnings released: NT$0.43 loss per share (vs NT$0.43 loss in 3Q 2024)Third quarter 2025 results: NT$0.43 loss per share (further deteriorated from NT$0.43 loss in 3Q 2024). Revenue: NT$67.4m (down 36% from 3Q 2024). Net loss: NT$42.1m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Reported Earnings • Sep 03Second quarter 2025 earnings released: NT$0.55 loss per share (vs NT$0.62 loss in 2Q 2024)Second quarter 2025 results: NT$0.55 loss per share. Revenue: NT$86.0m (down 4.0% from 2Q 2024). Net loss: NT$53.5m (loss widened 20% from 2Q 2024).Reported Earnings • May 16First quarter 2025 earnings released: NT$0.46 loss per share (vs NT$0.62 loss in 1Q 2024)First quarter 2025 results: NT$0.46 loss per share. Revenue: NT$109.7m (up 76% from 1Q 2024). Net loss: NT$36.5m (loss widened 1.3% from 1Q 2024).Reported Earnings • Mar 19Full year 2024 earnings released: NT$2.52 loss per share (vs NT$1.82 loss in FY 2023)Full year 2024 results: NT$2.52 loss per share (further deteriorated from NT$1.82 loss in FY 2023). Revenue: NT$381.3m (up 30% from FY 2023). Net loss: NT$172.8m (loss widened 66% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.お知らせ • Mar 14Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025, at 09:00 Taipei Standard Time. Location: 2 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwanお知らせ • Mar 04Kuangli Bio-Tech Holdings Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025分析記事 • Feb 25Kuangli Bio-Tech Holdings Co., Ltd. (TWSE:6431) Stock Rockets 25% As Investors Are Less Pessimistic Than ExpectedKuangli Bio-Tech Holdings Co., Ltd. ( TWSE:6431 ) shareholders would be excited to see that the share price has had a...Reported Earnings • Nov 19Third quarter 2024 earnings released: NT$0.43 loss per share (vs NT$0.58 loss in 3Q 2023)Third quarter 2024 results: NT$0.43 loss per share (improved from NT$0.58 loss in 3Q 2023). Revenue: NT$105.2m (up 84% from 3Q 2023). Net loss: NT$30.9m (loss narrowed 6.3% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (NT$1.27b market cap, or US$39.2m).お知らせ • Nov 05Kuangli Bio-Tech Holdings Co., Ltd. to Report Q3, 2024 Results on Nov 12, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q3, 2024 results on Nov 12, 2024Reported Earnings • Aug 30Second quarter 2024 earnings released: NT$0.62 loss per share (vs NT$0.15 loss in 2Q 2023)Second quarter 2024 results: NT$0.62 loss per share (further deteriorated from NT$0.15 loss in 2Q 2023). Revenue: NT$89.5m (down 14% from 2Q 2023). Net loss: NT$44.5m (loss widened 406% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.New Risk • Aug 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 29% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$1.23b market cap, or US$38.5m).お知らせ • Aug 17Kuangli Bio-Tech Holdings Co., Ltd. to Report Q2, 2024 Results on Aug 26, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q2, 2024 results on Aug 26, 2024New Risk • May 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$787.8m market cap, or US$24.4m).お知らせ • May 08+ 1 more updateKuangli Bio-Tech Holdings Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$732.7m market cap, or US$22.7m).分析記事 • Mar 22Kuangli Bio-Tech Holdings Co., Ltd.'s (TWSE:6431) Shareholders Might Be Looking For ExitWhen close to half the companies in the Electronic industry in Taiwan have price-to-sales ratios (or "P/S") below 1.6x...New Risk • Dec 01New major risk - Revenue and earnings growthEarnings have declined by 9.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$935.9m market cap, or US$29.8m).New Risk • Nov 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Market cap is less than US$100m (NT$947.3m market cap, or US$29.3m).New Risk • Sep 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$69m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risk Market cap is less than US$100m (NT$1.02b market cap, or US$31.9m).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 07Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022.分析記事 • Mar 31We're Not Worried About Kuangli Photoelectric Technology's (TPE:6431) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Is New 90 Day High Low • Feb 22New 90-day high: NT$34.10The company is up 16% from its price of NT$29.30 on 24 November 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 23% over the same period.分析記事 • Feb 03Did Business Growth Power Kuangli Photoelectric Technology's (TPE:6431) Share Price Gain of 248%?When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...Is New 90 Day High Low • Jan 29New 90-day high: NT$31.70The company is up 19% from its price of NT$26.70 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 30% over the same period.分析記事 • Dec 09We Think Kuangli Photoelectric Technology (TPE:6431) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Is New 90 Day High Low • Oct 29New 90-day low: NT$26.80The company is down 2.0% from its price of NT$27.35 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Electronic industry, which is also down 2.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Kuangli Bio-Tech Holdings は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TWSE:6431 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026353-195-129-118N/A12/31/2025377-193-155-145N/A9/30/2025387-193-170-159N/A6/30/2025425-182-87-73N/A3/31/2025429-173-105-90N/A12/31/2024381-173-83-65N/A9/30/2024333-148-86-75N/A6/30/2024285-150-54-45N/A3/31/2024300-114-102-85N/A12/31/2023293-104-88-62N/A9/30/2023325-78-46-13N/A6/30/2023380-50-69-32N/A3/31/2023337-66-219N/A12/31/2022342-68-43-9N/A9/30/2022386-64-70-31N/A6/30/2022402-64-2328N/A3/31/202241821-489N/A12/31/202133344-1922N/A9/30/202115569-326N/A6/30/20216344-63-47N/A3/31/202151-35-80N/A12/31/202087-4208N/A9/30/2020333-79-34-29N/A6/30/2020413-34-54-50N/A3/31/2020431-26-78-75N/A12/31/2019425-28N/A-92N/A9/30/2019228-21N/A-63N/A6/30/2019143-17N/A-21N/A3/31/2019110-4N/A-10N/A12/31/2018100-19N/A-22N/A9/30/2018100-74N/A-22N/A6/30/201888-128N/A-31N/A3/31/201893-157N/A-56N/A12/31/2017107-159N/A-48N/A9/30/2017138-187N/A-7N/A6/30/2017159-197N/A-25N/A3/31/2017183-265N/A-4N/A12/31/2016211-271N/A10N/A9/30/2016252-295N/A-11N/A6/30/2016310-263N/A11N/A3/31/2016377-212N/A-2N/A12/31/2015417-208N/A26N/A9/30/2015429-111N/A164N/A6/30/2015576-91N/A262N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6431の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6431の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6431の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6431の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6431の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6431の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YTech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 22:16終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kuangli Bio-Tech Holdings Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 20First quarter 2026 earnings released: NT$0.40 loss per share (vs NT$0.46 loss in 1Q 2025)First quarter 2026 results: NT$0.40 loss per share. Revenue: NT$85.8m (down 22% from 1Q 2025). Net loss: NT$38.7m (loss widened 6.0% from 1Q 2025).
Reported Earnings • Mar 20Full year 2025 earnings released: NT$2.07 loss per share (vs NT$2.52 loss in FY 2024)Full year 2025 results: NT$2.07 loss per share. Revenue: NT$377.0m (down 1.1% from FY 2024). Net loss: NT$193.0m (loss widened 12% from FY 2024).
お知らせ • Mar 16Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026. Location: 15 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwan
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$170m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$3.04b market cap, or US$97.2m).
Reported Earnings • Nov 18Third quarter 2025 earnings released: NT$0.43 loss per share (vs NT$0.43 loss in 3Q 2024)Third quarter 2025 results: NT$0.43 loss per share (further deteriorated from NT$0.43 loss in 3Q 2024). Revenue: NT$67.4m (down 36% from 3Q 2024). Net loss: NT$42.1m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Reported Earnings • Sep 03Second quarter 2025 earnings released: NT$0.55 loss per share (vs NT$0.62 loss in 2Q 2024)Second quarter 2025 results: NT$0.55 loss per share. Revenue: NT$86.0m (down 4.0% from 2Q 2024). Net loss: NT$53.5m (loss widened 20% from 2Q 2024).
Reported Earnings • May 16First quarter 2025 earnings released: NT$0.46 loss per share (vs NT$0.62 loss in 1Q 2024)First quarter 2025 results: NT$0.46 loss per share. Revenue: NT$109.7m (up 76% from 1Q 2024). Net loss: NT$36.5m (loss widened 1.3% from 1Q 2024).
Reported Earnings • Mar 19Full year 2024 earnings released: NT$2.52 loss per share (vs NT$1.82 loss in FY 2023)Full year 2024 results: NT$2.52 loss per share (further deteriorated from NT$1.82 loss in FY 2023). Revenue: NT$381.3m (up 30% from FY 2023). Net loss: NT$172.8m (loss widened 66% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 14Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025, at 09:00 Taipei Standard Time. Location: 2 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwan
お知らせ • Mar 04Kuangli Bio-Tech Holdings Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025
分析記事 • Feb 25Kuangli Bio-Tech Holdings Co., Ltd. (TWSE:6431) Stock Rockets 25% As Investors Are Less Pessimistic Than ExpectedKuangli Bio-Tech Holdings Co., Ltd. ( TWSE:6431 ) shareholders would be excited to see that the share price has had a...
Reported Earnings • Nov 19Third quarter 2024 earnings released: NT$0.43 loss per share (vs NT$0.58 loss in 3Q 2023)Third quarter 2024 results: NT$0.43 loss per share (improved from NT$0.58 loss in 3Q 2023). Revenue: NT$105.2m (up 84% from 3Q 2023). Net loss: NT$30.9m (loss narrowed 6.3% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (NT$1.27b market cap, or US$39.2m).
お知らせ • Nov 05Kuangli Bio-Tech Holdings Co., Ltd. to Report Q3, 2024 Results on Nov 12, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q3, 2024 results on Nov 12, 2024
Reported Earnings • Aug 30Second quarter 2024 earnings released: NT$0.62 loss per share (vs NT$0.15 loss in 2Q 2023)Second quarter 2024 results: NT$0.62 loss per share (further deteriorated from NT$0.15 loss in 2Q 2023). Revenue: NT$89.5m (down 14% from 2Q 2023). Net loss: NT$44.5m (loss widened 406% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
New Risk • Aug 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 29% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$1.23b market cap, or US$38.5m).
お知らせ • Aug 17Kuangli Bio-Tech Holdings Co., Ltd. to Report Q2, 2024 Results on Aug 26, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q2, 2024 results on Aug 26, 2024
New Risk • May 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$787.8m market cap, or US$24.4m).
お知らせ • May 08+ 1 more updateKuangli Bio-Tech Holdings Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024
New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$732.7m market cap, or US$22.7m).
分析記事 • Mar 22Kuangli Bio-Tech Holdings Co., Ltd.'s (TWSE:6431) Shareholders Might Be Looking For ExitWhen close to half the companies in the Electronic industry in Taiwan have price-to-sales ratios (or "P/S") below 1.6x...
New Risk • Dec 01New major risk - Revenue and earnings growthEarnings have declined by 9.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$935.9m market cap, or US$29.8m).
New Risk • Nov 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Market cap is less than US$100m (NT$947.3m market cap, or US$29.3m).
New Risk • Sep 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$69m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risk Market cap is less than US$100m (NT$1.02b market cap, or US$31.9m).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 07Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022.
分析記事 • Mar 31We're Not Worried About Kuangli Photoelectric Technology's (TPE:6431) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Is New 90 Day High Low • Feb 22New 90-day high: NT$34.10The company is up 16% from its price of NT$29.30 on 24 November 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 23% over the same period.
分析記事 • Feb 03Did Business Growth Power Kuangli Photoelectric Technology's (TPE:6431) Share Price Gain of 248%?When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...
Is New 90 Day High Low • Jan 29New 90-day high: NT$31.70The company is up 19% from its price of NT$26.70 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 30% over the same period.
分析記事 • Dec 09We Think Kuangli Photoelectric Technology (TPE:6431) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Is New 90 Day High Low • Oct 29New 90-day low: NT$26.80The company is down 2.0% from its price of NT$27.35 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Electronic industry, which is also down 2.0% over the same period.